Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

$ILMNPress releaseJul 30, 2026, 4:05 PM ETRead the release

Illumina reported Q2 revenue of $1.16 billion, up 9.5% year-over-year, with ROW organic revenue growth reaching 8.1% driven by demand for NovaSeq X. Management raised full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP EPS guidance to $5.30-$5.40, citing momentum in clinical sequencing applications.

Key figures

Eps: 1.35
Revenue: 1159000000
Guidance: FY26 revenue $4.60-$4.64B, raised from $4.52-$4.62B; Non-GAAP EPS $5.30-$5.40, raised from $5.15-$5.30
Revenue Yoy: 9.5%
Fcf: 162000000
Gross margin: 66.4%
Non gaap eps: 1.31
Row organic growth: 8.1%
Operating margin gaap: 21.1%
Operating margin non gaap: 22.5%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.